Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

University of British Columbia

$35,000.00

Dynamics of Arginine Methylation in Cellular Processes

FY 2014-15

Summary
Background. The methylation of arginine residues within proteins by enzymes called protein arginine N-methyltransferases (PRMTs), is a modification (PTM) found predominantly in chromatin-associated and RNA-binding proteins, and has been shown to play regulatory roles in many important cellular processes. Once proteolytically liberated, free dimethylated arginines can competitively inhibit nitric oxide synthases and prevent their functions in regulating vascular tone, pain, neurotransmission, and the inflammatory response to microorganisms. This PTM has recently emerged as a biomarker for a growing list of diseases including cancer, cardiovascular, and inflammatory lung diseases. Unlike other transient PTMs, however, arginine methylation is a stable mark on proteins. For the past few years my laboratory has established techniques to study arginine methylation so that we may determine how PRMTs contribute to cellular programming. Recently, we were able to see using proteomic techniques large changes in arginine methylation between proteins from cultured human lung epithelial cells treated with tumor necrosis factor-alpha or lipopolysaccharide and proteins from untreated cells. These experiments also revealed protein mediators of the inflammatory response as new PRMT substrates. Research Program Objectives. The long-term objective of our lab is to understand the independent and combined contributions of PRMTs toward cell proliferation, differentiation, and death. One of our short-term goals, for which we are requesting NSERC support, is to establish PRMT-specific arginine methylation networks in different inflammatory response pathways. Scientific Approach. We will subject cultured human cell lines to treatments that cause an NF-kappaB-mediated inflammatory responses. Proteins from treated and untreated control cells will be harvested and either blotted with dimethylarginine-specific antibodies or used for proteomic analysis as part of an ongoing collaboration with Drs. Leonard Foster and Nichollas Scott at the UBC Centre for High-Throughput Biology. Our proteomic approach takes advantage of a recently reported enrichment strategy for methylated peptides using hydrophilic interaction liquid chromatography prior to sample analysis by mass spectrometry. Methylated proteins from control and treatment groups will then be compared for relative quantitation, allowing us to observe changes in PTMs as a way to establish arginine methylation networks in inflammation. The next step will be to determine specific PRMT involvement in inflammatory pathways either by employing cell-based assays in which specific PRMT expression levels will be decreased via siRNA, or by pharmacologically inhibiting specific PRMTs in cultured cells with small molecules. We will also co-immunoprecipitate methylated proteins from cells to determine which PRMTs associate with their substrates by Western blot and mass spectrometry. These substrates will then be tested with in vitro methylation assays to demonstrate PRMT substrate specificity. Impact. Arginine methylation has been demonstrated to perform specific functions in important cellular processes, but this PTM has yet to be studied in the broader context of the cell. By observing arginine methylation changes on the global scale of the proteome, we will identify substrates whose modifications may serve critical roles in inflammatory events, and demonstrate how this PTM participates in various signaling pathways. This work will provide mechanistic insight into how the integration of PRMT activities contributes to cellular programming and ultimately determines cell fate. Our findings should impact the fields of cancer biology, inflammation, and biochemistry.
Program
Discovery Grants Program - Individual
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
RGPIN-2014-06560
Name nom
Frankel, Adam
Department département
Pharmaceutical Sciences
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2014
Competition year année de concours
2014
Award amount
35000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5404
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Enzymes
Research subject fr
Enzymes
Partie
1
Nb partie
1
Application title
Dynamics of Arginine Methylation in Cellular Processes
Keyword
NSERC
Application summary
Background. The methylation of arginine residues within proteins by enzymes called protein arginine N-methyltransferases (PRMTs), is a modification (PTM) found predominantly in chromatin-associated and RNA-binding proteins, and has been shown to play regulatory roles in many important cellular processes. Once proteolytically liberated, free dimethylated arginines can competitively inhibit nitric oxide synthases and prevent their functions in regulating vascular tone, pain, neurotransmission, and the inflammatory response to microorganisms. This PTM has recently emerged as a biomarker for a growing list of diseases including cancer, cardiovascular, and inflammatory lung diseases. Unlike other transient PTMs, however, arginine methylation is a stable mark on proteins. For the past few years my laboratory has established techniques to study arginine methylation so that we may determine how PRMTs contribute to cellular programming. Recently, we were able to see using proteomic techniques large changes in arginine methylation between proteins from cultured human lung epithelial cells treated with tumor necrosis factor-alpha or lipopolysaccharide and proteins from untreated cells. These experiments also revealed protein mediators of the inflammatory response as new PRMT substrates. Research Program Objectives. The long-term objective of our lab is to understand the independent and combined contributions of PRMTs toward cell proliferation, differentiation, and death. One of our short-term goals, for which we are requesting NSERC support, is to establish PRMT-specific arginine methylation networks in different inflammatory response pathways. Scientific Approach. We will subject cultured human cell lines to treatments that cause an NF-kappaB-mediated inflammatory responses. Proteins from treated and untreated control cells will be harvested and either blotted with dimethylarginine-specific antibodies or used for proteomic analysis as part of an ongoing collaboration with Drs. Leonard Foster and Nichollas Scott at the UBC Centre for High-Throughput Biology. Our proteomic approach takes advantage of a recently reported enrichment strategy for methylated peptides using hydrophilic interaction liquid chromatography prior to sample analysis by mass spectrometry. Methylated proteins from control and treatment groups will then be compared for relative quantitation, allowing us to observe changes in PTMs as a way to establish arginine methylation networks in inflammation. The next step will be to determine specific PRMT involvement in inflammatory pathways either by employing cell-based assays in which specific PRMT expression levels will be decreased via siRNA, or by pharmacologically inhibiting specific PRMTs in cultured cells with small molecules. We will also co-immunoprecipitate methylated proteins from cells to determine which PRMTs associate with their substrates by Western blot and mass spectrometry. These substrates will then be tested with in vitro methylation assays to demonstrate PRMT substrate specificity. Impact. Arginine methylation has been demonstrated to perform specific functions in important cellular processes, but this PTM has yet to be studied in the broader context of the cell. By observing arginine methylation changes on the global scale of the proteome, we will identify substrates whose modifications may serve critical roles in inflammatory events, and demonstrate how this PTM participates in various signaling pathways. This work will provide mechanistic insight into how the integration of PRMT activities contributes to cellular programming and ultimately determines cell fate. Our findings should impact the fields of cancer biology, inflammation, and biochemistry.